Shares of Baxter International Inc. (NYSE:BAX) have been given a consensus recommendation of “Hold” by the fourteen analysts that are covering the company. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $49.00.
A number of research firms have recently weighed in on BAX. RBC Capital Markets restated a “hold” rating and issued a $50.00 price target (up from $47.00) on shares of Baxter International in a report on Wednesday, July 27th. Royal Bank Of Canada raised their price target on shares of Baxter International from $47.00 to $50.00 and gave the company a “sector perform” rating in a report on Wednesday, July 27th. Zacks Investment Research upgraded shares of Baxter International from a “sell” rating to a “hold” rating and set a $54.00 price target on the stock in a report on Wednesday, July 27th. Argus restated a “hold” rating on shares of Baxter International in a report on Monday, August 15th. Finally, JPMorgan Chase & Co. raised their price target on shares of Baxter International from $45.00 to $48.00 and gave the company a “neutral” rating in a report on Wednesday, July 27th.
Shares of Baxter International (NYSE:BAX) opened at 47.01 on Friday. The firm’s 50-day moving average is $47.05 and its 200-day moving average is $45.50. The stock has a market capitalization of $25.57 billion, a PE ratio of 5.40 and a beta of 0.70. Baxter International has a one year low of $32.92 and a one year high of $49.49.
Baxter International (NYSE:BAX) last released its quarterly earnings results on Tuesday, July 26th. The company reported $0.46 earnings per share for the quarter, beating analysts’ consensus estimates of $0.40 by $0.06. Baxter International had a net margin of 47.74% and a return on equity of 10.70%. The business had revenue of $2.60 billion for the quarter, compared to analysts’ expectations of $2.51 billion. During the same period last year, the business earned $1.00 EPS. The company’s revenue was up 4.4% compared to the same quarter last year. On average, analysts expect that Baxter International will post $1.73 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Monday, October 3rd. Stockholders of record on Friday, September 2nd were issued a dividend of $0.13 per share. This represents a $0.52 annualized dividend and a dividend yield of 1.11%. The ex-dividend date of this dividend was Wednesday, August 31st. Baxter International’s dividend payout ratio (DPR) is 5.99%.
Institutional investors have recently bought and sold shares of the stock. Trust Department MB Financial Bank N A raised its position in Baxter International by 4.1% in the second quarter. Trust Department MB Financial Bank N A now owns 1,746 shares of the company’s stock valued at $122,000 after buying an additional 68 shares during the period. Balentine LLC raised its position in Baxter International by 12.6% in the second quarter. Balentine LLC now owns 3,176 shares of the company’s stock valued at $144,000 after buying an additional 356 shares during the period. Checchi Capital Advisers LLC raised its position in Baxter International by 1.9% in the second quarter. Checchi Capital Advisers LLC now owns 4,333 shares of the company’s stock valued at $196,000 after buying an additional 81 shares during the period. Cobblestone Capital Advisors LLC NY purchased a new position in Baxter International during the second quarter valued at $203,000. Finally, Pioneer Trust Bank N A OR purchased a new position in Baxter International during the second quarter valued at $203,000. 84.81% of the stock is owned by hedge funds and other institutional investors.
Baxter International Company Profile
Baxter International Inc, through its subsidiaries, provides a portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics, and pharmacy automation, software and services.
Receive News & Ratings for Baxter International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.